12.12.2024 00:55:06 CET | Thor Medical ASA | Mandatory notification of trade primary insiders
Oslo, Norway, 12 December 2024: Reference is made to the stock exchange announcement by Thor Medical ASA (the "Company") on 11 December 2024 regarding a private placement of new shares to be issued by the Company (the "Private Placement").
The following primary insiders and close associates have been allocated shares in the Private Placement, as further specified in the attached notification forms:
Scatec Innovation AS, a close associate of board member John Andersen, has been allocated 12,000,000 shares ;
Jasper Kurth, the CEO, has been allocated 400,000 shares;
Sindre Hassfjell the CTO, has been allocated 80,000 shares;
Alf Bjørseth, SVP Business Development, has been allocated 400,000 shares;
Ludvik Sandnes, the chair of the board, has been allocated 140,000 shares; and
B Good Industries AS, a close associated of primary insider Brede Ellingsæter the CFO, has been allocated 400,000 shares;
This information is subject to disclosure requirements pursuant to the EU Market Abuse Regulation article 19 (3) and the Norwegian Securities Trading Act section 5-12.
Contacts
Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
To learn more, visit www.thormedical.no – https://www.thormedical.no.
Attachments
Download announcement as PDF.pdf
20241211 – Primary insider notifications.pdf
